BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 25854514)

  • 1. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
    Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
    Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
    Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z; Wang H; Li Y; Qin Y; Xu L; Bowers DJ; Gangoda M; Li X; Yang HB; Zheng YR
    Chem Commun (Camb); 2018 Jan; 54(7):731-734. PubMed ID: 29303526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(IV) prodrug with unique mode of action.
    Ma L; Ma R; Wang Y; Zhu X; Zhang J; Chan HC; Chen X; Zhang W; Chiu SK; Zhu G
    Chem Commun (Camb); 2015 Apr; 51(29):6301-4. PubMed ID: 25644651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
    Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
    Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles.
    Min Y; Li J; Liu F; Yeow EK; Xing B
    Angew Chem Int Ed Engl; 2014 Jan; 53(4):1012-6. PubMed ID: 24311528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
    Shi H; Cheng Q; Yuan S; Ding X; Liu Y
    Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance.
    Ma J; Li L; Yue K; Li Y; Liu H; Wang PG; Wang C; Wang J; Luo W; Xie S
    Bioorg Chem; 2020 Jun; 99():103768. PubMed ID: 32217375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY; Wang DB; Song XQ; Wu YG; Chen Q; Zhao CL; Li JY; Cheng SH; Xu JY
    Eur J Med Chem; 2018 Sep; 157():1292-1299. PubMed ID: 30195239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
    Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A platinum prodrug conjugated with a photosensitizer with aggregation-induced emission (AIE) characteristics for drug activation monitoring and combinatorial photodynamic-chemotherapy against cisplatin resistant cancer cells.
    Yuan Y; Zhang CJ; Liu B
    Chem Commun (Camb); 2015 May; 51(41):8626-9. PubMed ID: 25898264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hybrid inorganic (nonporous silica)/organic (alginate) core-shell platform for targeting a cisplatin-based Pt(IV) anticancer prodrug.
    Ravera M; Gabano E; Bonzani D; Zanellato I; Arrais A; Cantamessa S; Biggiogera M; Osella D
    J Inorg Biochem; 2018 Dec; 189():185-191. PubMed ID: 30312905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
    Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
    Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Quadruple-Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines.
    Petruzzella E; Braude JP; Aldrich-Wright JR; Gandin V; Gibson D
    Angew Chem Int Ed Engl; 2017 Sep; 56(38):11539-11544. PubMed ID: 28759160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel hypoxia-targeting Pt(iv) prodrugs.
    Xu Z; Zhao J; Gou S; Xu G
    Chem Commun (Camb); 2017 Mar; 53(26):3749-3752. PubMed ID: 28303266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclodextrin capped gold nanoparticles as a delivery vehicle for a prodrug of cisplatin.
    Shi Y; Goodisman J; Dabrowiak JC
    Inorg Chem; 2013 Aug; 52(16):9418-26. PubMed ID: 23889547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
    Chen Q; Yang Y; Lin X; Ma W; Chen G; Li W; Wang X; Yu Z
    Chem Commun (Camb); 2018 May; 54(42):5369-5372. PubMed ID: 29744485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Iron Oxide Nanocarrier Loaded with a Pt(IV) Prodrug and Immunostimulatory dsRNA for Combining Complementary Cancer Killing Effects.
    Hernández-Gil J; Cobaleda-Siles M; Zabaleta A; Salassa L; Calvo J; Mareque-Rivas JC
    Adv Healthc Mater; 2015 May; 4(7):1034-42. PubMed ID: 25846677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M; Gabano E; Zanellato I; Perin E; Arrais A; Osella D
    Dalton Trans; 2016 Nov; 45(43):17233-17240. PubMed ID: 27722707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative mechanism of action of the DNP Pt
    Krasnovskaya O; Spector D; Erofeev A; Gorelkin P; Akasov R; Skvortsov D; Trigub A; Vlasova K; Semkina A; Zyk N; Beloglazkina E; Majouga A
    Dalton Trans; 2021 Jun; 50(23):7922-7927. PubMed ID: 34037020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.